ViCardia is developing a new class of precision medicines targeting the metabolism of dysfunctional mitochondria. ViCardia’s lead indication is heart failure – both chronic and advanced forms. Other indications include rare and orphan diseases, chronic kidney failure, and cardiac muscle atrophy in space travel. 

Our core technology is a conjugate that combines GP-531, the active compound, with a cardiac targeting peptide that delivers the therapeutic dose directly to the affected cardiomyocytes. The conjugate represents a technological breakthrough over existing systemic treatments for heart failure.